Inderal

Selected form

Propranolol

Method of action: Antianginal, Antiarrhythmic, Antihypertensive, Beta Blocking Agents, Hypotensive, Uterotonizing

Treatment option: Hypertension, Headache, Benign Essential Tremor, Cardiomyopathy, Migraine, Parkinsonism, Heart Attack, Angina Pectoris, Thyrotoxicosis, Pheochromocytoma

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Inderal

Quick Facts

Property	Description
Active ingredient	Propranolol hydrochloride
Form	Tablet, extended-release capsule, solution
Pharmacological class	Beta-adrenergic blocking agent (Beta-blocker)
Common use	Cardiovascular regulation, physiological tension control
Origin	Synthetic

Propranolol: Definition and Pharmacological Classification

The medicinal entity commonly associated with the brand name Inderal is Propranolol hydrochloride, which serves as the sole active ingredient. This compound is a synthetic small molecule classified as a first-generation beta-adrenergic blocking agent, universally known as a beta-blocker. Propranolol is specifically designated as a non-selective beta-blocker, meaning its mechanism involves blocking both beta1 and beta2 adrenergic receptors throughout the body, providing a broad systemic effect. This dual action is a differentiating factor, as many newer beta-blockers are designed to be selective, targeting the heart more specifically.

How Propranolol Works and Its General Purpose

The general purpose of this prescribed medication is to achieve systemic cardiovascular stabilization by moderating the body’s physical response to stress and activity. Propranolol functions by competitively inhibiting the effects of naturally occurring stress hormones, such as adrenaline, at receptor sites. This action fundamentally helps to reduce the heart’s rate and force of contraction and prevents the inappropriate tightening of blood vessels. By regulating these processes, the medicine works to control the physiological effects of an overactive sympathetic nervous system, often used in scenarios requiring sustained control of heart rate and rhythm.

Available Forms and Administration Types

Propranolol is a drug intended for systemic administration via both oral and intravenous pathways. A distinctive aspect of the product line, such as Inderal LA (Long-Acting), is the availability of the extended-release capsule, which provides a differentiated delivery profile for a more sustained, consistent release of the active ingredient over time. Additional forms include the standard tablet for immediate action, an oral solution, and a solution for injection for specialized therapeutic needs. The availability of these distinct dosage forms ensures that the medicine’s stabilizing effect can be managed according to the required onset and duration of action.

What side effects are possible with Inderal?

Possible Side Effects and Safety Information

The safety profile of propranolol, the active ingredient in Inderal, is strictly defined by government regulatory documents, classifying potential adverse reactions by frequency and physiological system. This information is non-advisory and focuses only on what is officially documented in sources such as the FDA Prescribing Information and the EMA Summary of Product Characteristics (SmPC).

Frequency-Classified Adverse Reactions

The most frequently documented effects are classified as Common (affecting more than 1 in 100 people) and typically include bradycardia (slow heart rate), fatigue, lethargy, dizziness, and cold extremities. Less common effects may involve gastrointestinal disturbances such as nausea and diarrhea.

System-Organ-Class Groupings

Adverse reactions are primarily documented within the Cardiac Disorders (e.g., hypotension, heart block) and Nervous System Disorders (e.g., sleep disturbances, vivid dreams, confusion). Effects in the Respiratory System (e.g., bronchospasm) and Metabolism/Nutrition (e.g., hypoglycemia) are also listed in official labeling.

Serious Safety Considerations

Specific serious adverse reactions are documented, including severe cardiac failure, severe hypoglycemia, and rare but clinically important conditions such as severe cutaneous reactions. Regulatory labels also define key safety restrictions: use is strictly contraindicated in individuals with bronchial asthma or a history of bronchospasm, decompensated heart failure, and certain pre-existing heart block conditions.

Exposure-Related Safety Note

Official labeling warns that the abrupt discontinuation of propranolol therapy, particularly in patients with heart disease, is associated with a risk of exacerbation of angina pectoris and, in rare instances, myocardial infarction.

Overdose and Emergency Response

An overdose of propranolol hydrochloride (Inderal) is associated with severe, systemic manifestations documented in regulatory labeling. The primary presentations involve profound depression of the cardiovascular and central nervous systems, leading to potentially life-threatening outcomes classified as severe by regulatory authorities.

Documented overdose effects often include bradycardia (abnormally slow heart rate) and severe hypotension (low blood pressure), which may progress to cardiogenic shock or cardiac arrest. Other serious manifestations formally listed in labeling are bronchospasm, seizures, and a decreased level of consciousness potentially leading to coma. The physiological systems affected are explicitly stated as the cardiovascular, respiratory, central nervous, and metabolic systems.

For any suspected or confirmed overdose, regulatory guidance mandates that the user seek immediate medical attention and contact emergency services. This urgent action is required because, as officially stated, no specific antidote is known for Propranolol overdose. Therefore, management relies entirely on sophisticated supportive and symptomatic treatment, such as the use of intravenous Glucagon or Atropine to counteract severe cardiac depression. A specific population consideration is the elevated risk of hypoglycemia (low blood sugar) documented in pediatric patients following an overdose, requiring monitoring.

Therapeutic Uses of Inderal

The medication may be part of symptomatic management for conditions marked by increased physiological stress, commonly used across domains where additional symptomatic support is needed. For propranolol, the core therapeutic focus includes cardiovascular, neurological, and prophylactic management.

What Propranolol Treats: Main Uses and Benefits

The medication may be part of symptomatic management for several core therapeutic areas. It is generally used to help with chronic hypertension, certain arrhythmias, and may be part of secondary prevention after an acute heart event. It is also relevant for easing recurrent angina pectoris. In the neurological domain, it is applied to manage essential tremor and serves as a prophylactic treatment to reduce the frequency of migraine headaches. The medication may assist with managing acute physical symptoms related to physiological tension, such as those experienced in performance anxiety or thyrotoxicosis.

This use supports the management of symptoms related to systemic imbalance, such as elevated blood pressure and rapid heart rate, which contributes to easing the overall symptom load.

“This application may offer symptomatic relief that helps patients cope more steadily with symptom fluctuations and supports general well-being during symptomatic phases.”

Quick Fact: Relief for Episodic and Chronic Symptoms

The medication is commonly used to help manage both recurrent, episodic symptoms (like migraines and situational tremor) and chronic, stable conditions (like hypertension and angina), which may support the maintenance of functional stability in these diverse contexts.

Regulatory References

NIH DailyMed official drug label

Eligibility and Restrictions for Use

The official regulatory profile for Inderal (Propranolol) defines patient eligibility by strict exclusions and conditional use guidelines. The medicine is contraindicated and must not be used by specific populations due to the risk of severe adverse events.

These absolute prohibitions include patients diagnosed with Cardiogenic Shock, Overt or Decompensated Cardiac Failure, or severe Sinus Bradycardia or Heart Block (greater than first degree, unless a pacemaker is present). Use is also prohibited for individuals with Bronchial Asthma or a history of bronchospasm, or Metabolic Acidosis.

Population Restriction	Condition/Status
Not Recommended	Pregnancy and Lactation (due to excretion in breast milk)
Conditional Use	Hepatic or Renal Impairment (requires caution and monitoring)
Conditional Use	Diabetes Mellitus (may mask signs of hypoglycemia)
Conditional Use	Older Adults (treatment should start at the lowest dose)
Conditional Use	Pheochromocytoma (must precede with an alpha-blocker)
Limited Eligibility	Pediatric patients (use is established only for specific indications with minimum age thresholds)

This eligibility profile mandates careful monitoring and dosage adjustment for populations with compromised organ function, reflecting the official regulatory criteria for safe use.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Propranolol’s official interaction profile is structured around both pharmacokinetic (exposure-altering) and pharmacodynamic (additive effect) patterns as documented in regulatory labeling.

Contraindicated Combinations

Co-administration with non-dihydropyridine calcium channel blockers such as Verapamil and Diltiazem is contraindicated. This restriction exists due to the high risk of additive effects that may lead to severe hypotension, profound bradycardia, and cardiac failure.

Pharmacokinetic and Exposure Effects

Interaction Type	Interacting Agents (Examples)	Official Outcome
Increased Exposure	Quinidine, Cimetidine, Fluoxetine	Increase Propranolol plasma concentrations by inhibiting metabolism (e.g., CYP2D6), with Quinidine documented to increase exposure 2- to 3-fold.
Decreased Exposure	Rifampin, Phenytoin, Montelukast	Decrease Propranolol plasma levels due to the induction of hepatic enzymes (e.g., CYP1A2 and CYP2C19), potentially reducing efficacy.

Pharmacodynamic Effects and Restrictions

Propranolol exhibits additive effects with other cardiac depressants (e.g., Digoxin, Clonidine) that increase the documented risk of significant bradycardia. The use of Insulin or other hypoglycemic agents may result in the prolongation of the hypoglycemic response and the masking of the warning sign of tachycardia.

Furthermore, specific timing rules apply: Propranolol and intravenous Verapamil/Diltiazem must not be administered within 48 hours of discontinuing the other. In addition to medicinal products, alcohol and cigarette smoking are documented to reduce Propranolol exposure via hepatic induction, while high-fat meals increase the drug’s systemic bioavailability.

Mechanism of Action

Core Mechanism: Non-Selective Beta-Adrenergic Blockade

Propranolol acts as a non-selective competitive antagonist, engaging both Beta-1 (beta1) and Beta-2 (beta2) adrenergic receptors throughout the body. By blocking these targets, the molecule prevents endogenous catecholamines like adrenaline and norepinephrine from initiating their signaling cascades. This interaction falls within the domain of the sympathetic nervous system (SNS), whose heightened activity may be modulated by this targeted receptor interference.

Molecular Cascade for Rate and Contractility

The action primarily affects beta1 receptor signaling in the heart, which suppresses the sequence involving cAMP and the influx of calcium ions (Ca^2+) into the cardiac cells. This molecular modification directly results in a negative chronotropic effect (slowing the heart rate) and a negative inotropic effect (reducing the force of contraction), thereby producing a reduced myocardial workload and oxygen demand.

Central and Renal Sympatholytic Regulation

Propranolol's high lipophilicity allows it to cross into the brain, where it modulates central vasomotor centers, leading to a diminished central sympathetic outflow. Concurrently, blockade of beta1 receptors in the kidneys suppresses the release of renin, a key mediator in the Renin-Angiotensin System (RAS), which further results in cardiovascular activity modulation through hormonal mechanisms.

Dosage and Administration Information

How to Use Propranolol: Administration Guidelines

Propranolol is administered via the oral route using immediate-release tablets, extended-release capsules, or oral solution. For specific acute needs, a solution for injection is available for intravenous use. The selection of the dosage form dictates the dosing schedule; immediate-release (IR) forms require divided doses, while extended-release (ER) forms are taken once daily.

The dosage regimen is determined by the indication, with specific ranges established for initiation, maintenance, and maximum daily intake.

Indication	Initial Oral Dose (Example)	Max Daily Dose (IR)
Hypertension (IR)	40 mg, two times daily	640 mg
Hypertension (ER)	80 mg, once daily	160 mg – 320 mg

The timing of administration differs by form. IR tablets are often taken before meals and at bedtime. ER capsules are taken consistently, either always with food or always on an empty stomach, to maintain predictable absorption. Furthermore, ER forms must be swallowed whole and must not be crushed, chewed, or opened.

Procedurally, if a dose is missed and it is near the next scheduled time, the missed dose is skipped. When increasing the dosage, titration is performed gradually, typically over intervals of three to seven days. Conversely, for patients discontinuing therapy, the dosage is gradually reduced over a period of at least a few weeks. For certain populations, a conservative approach is utilized, such as a conservative initial dose for older adults and body-weight-based calculations for pediatric patients.

Recent Clinical Evidence

Research evidence / Overview of studies for Inderal (Propranolol)

Research Evidence for Managing Cardiovascular Conditions

Recent analysis of the medicine's use for secondary prevention following a heart attack (myocardial infarction) has added nuance to older, foundational trials. While landmark studies from the 1970s and 1980s observed patterns associated with reduced all-cause mortality, contemporary studies suggest that this benefit may be less consistent today. For patients with preserved left ventricular ejection fraction (LVEF)—meaning the heart’s function is largely maintained—recent observational data and meta-analyses show that continuing the medicine beyond the initial year following an uncomplicated heart attack may not provide additional mortality benefits. Conversely, evidence continues to suggest favorable patterns in patients whose heart function is reduced.

Evidence from Studies of Neurological and Symptomatic Uses

Research has explored the medicine's application in essential tremor and migraine prophylaxis. For essential tremor, propranolol remains a commonly studied first-line option. Findings indicate that it may reduce the severity or amplitude of tremor in approximately 50% of studied patients, primarily affecting limb tremor. However, recent evidence highlights that a significant portion of individuals may not respond or may discontinue use due to associated effects.

For migraine headaches, contemporary systematic reviews reinforce that propranolol is frequently studied as a first-line agent. Recent large-scale, real-world data analyses suggest an association between the medicine's use and a lower occurrence of ischemic stroke in women with migraine, particularly those without aura. However, this association was not observed in men, underscoring the importance of studies that account for sex-specific findings.

Frequently Asked Questions (FAQ)

Common questions about Inderal (FAQ)

Q: Is Inderal a type of blood pressure medicine, a heart medicine, or both?

According to official regulatory documents, Inderal (propranolol) is indicated for treating high blood pressure (hypertension). It is also approved for use in various heart-related conditions, including controlling chest pain caused by angina pectoris and regulating the heart rhythm in conditions like atrial fibrillation.

Q: Does Inderal help with tremors that are not related to Parkinson's disease?

Yes, official product information confirms that propranolol is indicated for the management of familial or hereditary essential tremor. The official indication specifies that it is not intended for the treatment of tremor associated with Parkinson's disease.

Q: Are there any common foods or drinks that should be avoided while on Inderal?

Official labeling advises that while taking the extended-release capsule, consistency is important; it should be taken either always with food or always on an empty stomach to ensure predictable drug absorption. High-fat meals are also documented to increase the amount of drug that enters the body. Discussing your diet with a healthcare provider can help clarify specific dietary concerns.

Q: Can Inderal cause a low heart rate, and what counts as too low?

Bradycardia, or a slow heart rate, is a commonly reported adverse reaction listed in official safety information. While the regulatory label notes the drug can cause a marked decrease in heart rate, it does not define a specific numerical rate that constitutes 'too low' for an individual. Assessment of an individual's specific heart rate concerns is best done by a qualified healthcare professional.

Q: Is it common for people to gain weight when taking Inderal?

Weight gain is not typically listed as one of the most frequent adverse reactions in the core prescribing information. However, clinical literature related to the use of beta-blockers suggests weight gain is a possible effect that can occur in some individuals.

Q: Does Inderal have a different effect if you take it on an empty stomach?

Yes, the timing relative to meals can affect absorption. Immediate-release tablets are often taken before meals. For the extended-release capsules, official guidance is to take them consistently, either always with food or always on an empty stomach, to maintain a consistent level of the medicine in your system.

Q: Is Inderal considered safe to take during pregnancy (in general terms)?

Propranolol carries an FDA Pregnancy Category C classification. This classification indicates that the use of the drug during pregnancy requires a careful assessment of the potential benefits compared to the potential risks to the fetus.

Q: Can Inderal cause changes in sexual function?

Official safety labeling lists Male Impotence as an observed adverse reaction reported in patients taking propranolol. Any concerns about sexual function or other adverse effects should be discussed with a healthcare provider.

Q: Are there specific age groups where Inderal is generally avoided?

Official product information notes that the drug is contraindicated in premature infants with low birth weight. For other pediatric populations, use is established only for specific conditions, and dosages are carefully tailored based on the child’s size and condition.

Q: Is Inderal known to cause hair loss?

Alopecia, the medical term for hair loss, is listed in the official adverse reactions documentation as an observed effect reported by some patients using propranolol.

Q: Can you drive or operate machinery safely while taking Inderal?

Commonly reported adverse effects of this medicine include lightheadedness, dizziness, and fatigue. Regulatory safety information advises that these types of effects could potentially impair a person's ability to safely drive or operate heavy machinery.

Q: What research evidence supports the use of Inderal for migraine prevention?

Propranolol is officially indicated for the prophylaxis, or prevention, of common migraine headaches. Official documents clarify that the drug’s effectiveness for treating an acute migraine attack (one that is already occurring) has not been established.

Q: Is Inderal a long-term medicine, or is it typically used short-term?

Regulatory documents mandate that if therapy is discontinued, the dosage must be gradually reduced over a period of several weeks. This requirement is typically in place for drugs intended for long-term maintenance use.

Q: Are there any specific lab tests needed before starting Inderal?

While the official prescribing information does not mandate specific pre-treatment tests, it does note that in patients with high blood pressure, use has been associated with elevated levels of substances like serum potassium and certain liver enzymes. This suggests that monitoring of these parameters may occur during treatment.

Q: Why is Inderal sometimes used for essential tremor?

Propranolol is officially indicated for the use in essential tremor. The drug is thought to reduce the tremor’s amplitude via its action of blocking peripheral beta-adrenergic receptors throughout the body, though the full mechanism for tremor control is not explicitly detailed in official labels.

How should Inderal be stored and disposed of?

Storage and Disposal of Inderal (Propranolol Hydrochloride)

Inderal must be stored under specific conditions to maintain its integrity, as defined by regulatory labels.

Official Storage Requirements

Detail	Requirement
Temperature	Store at Controlled Room Temperature, 20 C to 25 C (68 F to 77 F).
Protection	Protect from freezing, excessive heat, light, and moisture.
Container	Keep in a well-closed container or the original package.

Handling and Disposal

The medication must be stored out of the sight and reach of children. Unused or expired Inderal must be disposed of in accordance with local requirements for pharmaceutical waste, and must not be thrown into household waste or wastewater.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.